From Padcev to PF-08634404: Pfizer's Oncology Growth Push

Pfizer's oncology revenues rose 3% to $4.17 billion in Q2 2026, with Padcev sales climbing 23% to $667 million following FDA approval for muscle-invasive bladder cancer. The company is advancing multiple pipeline candidates, including PF-08634404 in nine studies, and aims to have eight or more blockbuster oncology medicines by 2030. Pfizer trades at an attractive valuation with a Zacks Rank #3 (Hold) rating.